Online inquiry

IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3150MR)

This product GTTS-WQ3150MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets C3&C4 gene. The antibody can be applied in Cardiopulmonary bypass (CPB) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000064.4; NM_001002029.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 718; 721
UniProt ID P01024; P0C0L4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3150MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1461MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ11991MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ31MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ4502MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ9616MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ7142MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ15072MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ9846MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JTX-2011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW